Showing 2801-2810 of 6036 results for "".
- Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growthhttps://modernod.com/news/glaucoma-devices-expanding-role-to-drive-double-digit-market-growth/2479465/Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical devi
- Journal Highlights Desirable PK/PD Profiles of THR-687 and THR-149https://modernod.com/news/journal-highlights-desirable-pk-pd-profiles-of-thr-687-and-thr-149/2479450/Oxurion NV announced the publication of two related papers in the Journal of Pharmacokinetics and Pharmacodynamics entitled “Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach.” These papers describe the pharmacoki
- CooperVision MiSight 1-Day Contact Lens Approved in Chinahttps://modernod.com/news/coopervision-misight-1-day-contact-lens-approved-in-china/2479445/The Chinese National Medical Products Administration (NMPA) has approved CooperVision MiSight 1 day contact lenses for use within the country following a priority review. The innovative soft contact lenses have now become the first indicated product of any type in China that may slow the progress
- Regeneron Terminates Ocular Therapeutix Collaboration to Develop a Sustained-Release Formulation of Aflibercepthttps://modernod.com/news/regeneron-terminates-ocular-therapeutix-collaboration-to-develop-a-sustained-release-formulation-of-aflibercept/2479441/Ocular Therapeutix announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021. The collaboration with Regeneron was initially formed in 2016 for the development and commercialization of produ
- Aldeyra Therapeutics Receives Orphan Drug Designation from the FDA for ADX-2191 to Treat Retinitis Pigmentosahttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-drug-designation-from-the-fda-for-adx-2191-to-treat-retinitis-pigmentosa/2479434/Aldeyra Therapeutics announced that the FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation. In
- Oertli’s CataRhex 3 Device Now Equipped With Speep Pump Innovationhttps://modernod.com/news/oertlis-catarhex-3-device-now-equipped-with-speep-pump-innovation/2479420/Oertli Instrumente has expanded the CataRhex 3 to include the pump innovation, “SPEEP,” which is designed to provide more efficiency and precision in cataract surgery due to precise control of flow and vacuum. The CataRhex 3 is Oertli’s compact and portable surgical platf
- CooperVision Report Shows How ECPs Can Boost Contact Lens Trialhttps://modernod.com/news/coopervision-report-shows-how-ecps-can-boost-contact-lens-trial/2479418/A survey commissioned by CooperVision is shedding new light on the value of providing patients more sustainable contact lens options. Following the establishment of CooperVision’s partnership with Plastic Bank to make its clariti 1 day family the first net plastic neutral contact lenses in the US
- Refractive Surgery Council Reports Strongest H1 Laser Vision Correction (LVC) Procedure Volume Growth in Nearly a Decadehttps://modernod.com/news/refractive-surgery-council-reports-strongest-h1-laser-vision-correction-lvc-procedure-volume-growth-in-nearly-a-decade/2479384/The Refractive Surgery Council (RSC) reported the strongest first half laser vision correction (LVC) procedure volume growth in nearly a decade. The 82 percent year-over-year growth, fueled by the strong quarter-over-quarter performance, resulted in 231,503 LASIK, SMILE and PRK procedures perform
- EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-receives-preliminary-extension-to-pass-through-payment-status-for-dexycu/2479385/EyePoint Pharmaceuticals announced today that the company expects to receive a 9-month extension on Dexycu’s pass-through payment status, which otherwise would expire on March 31, 2022. On July 19, 2021, CMS released its 2022 draft Hospital Outpatient Prospective
- FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 for the Treatment of Stargardt Diseasehttps://modernod.com/news/fda-grants-alkeus-pharmaceuticals-breakthrough-therapy-designation-for-alk-001-c20-d3-vitamin-a-for-the-treatment-of-stargardt-disease/2479374/Alkeus Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease. ALK-001 (C20-D3-vitamin A) is a chemically-modified form of vitamin A developed to treat multiple retinal degenerati